Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Catherine Miller

Physician Assistant College Station, TX Physician Assistant

NPI 1013677442 CMS profile 11308934

2911 Texas Ave S Ste 202, College Station, TX 77845

Open in the dashboard

General payments

$8,465

468 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Catherine Miller of College Station, TX is reported in the CMS Open Payments database as having received $8,465 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,308 105
2024 General $2,201 107
2023 General $2,343 139
2022 General $1,613 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine Miller
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Catherine Miller were reported at $2,308. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Catherine Miller Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,613 $155 $48–$522 $149
2023 $2,343 $167 $52–$557 $160
2024 $2,201 $178 $55–$600 $164
2025 $2,308 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $1,709 120 payments
  2. AbbVie, Inc. $1,060 76 payments
  3. AstraZeneca Pharmaceuticals LP $898 21 payments
  4. Axsome Therapeutics, Inc. $480 19 payments
  5. Lilly USA, LLC $435 30 payments
  6. Pfizer Inc. $317 15 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $288 10 payments
  8. Corium, Inc. $261 14 payments
  9. Supernus Pharmaceuticals, Inc. $235 5 payments
  10. Teva Pharmaceuticals USA, Inc. $228 23 payments
  11. Other $2,554 135 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,370 467 payments
  2. Education $95 1 payment
Products named General payments · program years 2022–2025
  1. Ozempic $1,206 89 payments
  2. RYBELSUS $1,105 85 payments
  3. FARXIGA $633 11 payments
  4. BREZTRI $618 5 payments
  5. AIRSUPRA $601 10 payments
  6. QULIPTA $422 33 payments
  7. Wegovy $413 25 payments
  8. Sunosi $371 14 payments
  9. UBRELVY $352 25 payments
  10. VRAYLAR $286 18 payments
  11. Other $5,763 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,192

Median for Physician Assistant: 241

Drug cost

$132,854

Median for Physician Assistant: $4,110

Branded share of claims

22.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 12 $57,890
Ozempic Semaglutide Brand 26 $23,090
Januvia Sitagliptin Phosphate Brand 17 $15,662
Mounjaro Tirzepatide Brand 15 $14,440
Repatha Sureclick Evolocumab Brand 11 $9,091
Albuterol Sulfate Hfa Albuterol Sulfate Brand 46 $1,271
Rosuvastatin Calcium Generic 65 $1,017
Bupropion Xl Bupropion Hcl Brand 15 $830
Celecoxib Generic 17 $725
Levothyroxine Sodium Generic 79 $707

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$34,743

Of which drugs: $4,950

Medicare patients

168

Average age 71

Services billed

2,008

92 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 29%
Diabetes 24%
Atrial fibrillation 18%
Depression 13%
Cancer 12%
Heart failure 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 14 15 $4,354
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 700 $66
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 74 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $203
$203 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $180
$180 — —
Wegovy
  • Novo Nordisk Inc $149
$149 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $124
  • Lilly USA, LLC $19
$143 — —
VRAYLAR
  • AbbVie, Inc. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record